{
     "PMID": "26442993",
     "OWN": "NLM",
     "STAT": "MEDLINE",
     "DCOM": "20160822",
     "LR": "20160115",
     "IS": "1471-4159 (Electronic) 0022-3042 (Linking)",
     "VI": "135",
     "IP": "6",
     "DP": "2015 Dec",
     "TI": "Reduction in Abeta-induced cell death in the hippocampus of 17beta-estradiol-treated female rats is associated with an increase in IGF-I signaling and somatostatinergic tone.",
     "PG": "1257-71",
     "LID": "10.1111/jnc.13381 [doi]",
     "AB": "Several studies indicate that 17beta-estradiol (E2) protects against amyloid beta-peptide (Abeta)-induced cell death and activates factors associated with learning and memory, a function involving the hippocampal somatostatinergic system. As alterations in somatostatin have been demonstrated in Alzheimer's disease, we examined whether E2 prevents changes in the hippocampal somatostatinergic system induced by Abeta25-35 and cell death, as well as the possible involvement of leptin and insulin-like growth factor (IGF)-I signaling. We also measured the levels of Abeta proteases neprilysin and insulin-degrading-enzyme. Co-administration of E2 with Abeta25-35 reduced both its levels and cell death, in addition to preventing the Abeta-induced depletion of some somatostatinergic parameters. Activation of leptin and IGF-I pathways increased after E2 co-administration, and this correlated with changes in the somatostatinergic system. Changes in some components of this system were inversely related with Abeta levels and cell death. Moreover, neprilysin levels were increased only in Abeta plus E2-treated rats and E2 prevented the Abeta-induced insulin-degrading-enzyme reduction. Our results suggest that the E2-induced reduction in cell death is related to lower Abeta levels, probably because of IGF-I and somatostatin modulation of Abeta proteases. We asked how 17beta-estradiol (E2) protects against beta-amyloid (Abeta)-induced cell death. E2 co-administration prevents Abeta-produced depletion of hippocampal somatostatin (SRIF) by an IGF-I-mediated mechanism, being related this protective effect with an increase in Abeta proteases. Our results suggest that the E2-induced reduction in cell death is related to lower Abeta levels, probably because of SRIF modulation of Abeta proteases. CREB, cAMP response element-binding protein; IGF-I, insulin-like growth factor-I; STAT3, signal transducer and activator of transcription-3.",
     "CI": [
          "(c) 2015 International Society for Neurochemistry."
     ],
     "FAU": [
          "Perianes-Cachero, Aranzazu",
          "Canelles, Sandra",
          "Aguado-Llera, David",
          "Frago, Laura M",
          "Toledo-Lobo, Maria Val",
          "Carrera, Ivan",
          "Cacabelos, Ramon",
          "Chowen, Julie A",
          "Argente, Jesus",
          "Arilla-Ferreiro, Eduardo",
          "Barrios, Vicente"
     ],
     "AU": [
          "Perianes-Cachero A",
          "Canelles S",
          "Aguado-Llera D",
          "Frago LM",
          "Toledo-Lobo MV",
          "Carrera I",
          "Cacabelos R",
          "Chowen JA",
          "Argente J",
          "Arilla-Ferreiro E",
          "Barrios V"
     ],
     "AD": "Neurobiochemistry Group, Unit of Biochemistry and Molecular Biology, Facultad de Medicina, Universidad de Alcala, Alcala de Henares, Spain. Department of Endocrinology, Hospital Infantil Universitario Nino Jesus, Instituto de Investigacion La Princesa, Madrid, Spain. Centro de Investigacion Biomedica en Red de Fisiopatologia Obesidad y Nutricion (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain. Neurobiochemistry Group, Unit of Biochemistry and Molecular Biology, Facultad de Medicina, Universidad de Alcala, Alcala de Henares, Spain. Department of Endocrinology, Hospital Infantil Universitario Nino Jesus, Instituto de Investigacion La Princesa, Madrid, Spain. Centro de Investigacion Biomedica en Red de Fisiopatologia Obesidad y Nutricion (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain. Department of Biomedicine and Biotechnology, Universidad de Alcala, Alcala de Henares and Instituto Ramon y Cajal de Investigaciones Sanitarias (IRYCIS), Madrid, Spain. Department of Neuroscience, EuroEspes Biotechnology, Poligono de Bergondo, A Coruna, Spain. EuroEspes Biomedical Research Center, Institute for CNS Disorders and Chair of Genomic Medicine, University of Camilo Jose Cela, Villanueva de la Canada, Spain. Department of Endocrinology, Hospital Infantil Universitario Nino Jesus, Instituto de Investigacion La Princesa, Madrid, Spain. Centro de Investigacion Biomedica en Red de Fisiopatologia Obesidad y Nutricion (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain. Department of Endocrinology, Hospital Infantil Universitario Nino Jesus, Instituto de Investigacion La Princesa, Madrid, Spain. Centro de Investigacion Biomedica en Red de Fisiopatologia Obesidad y Nutricion (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain. Neurobiochemistry Group, Unit of Biochemistry and Molecular Biology, Facultad de Medicina, Universidad de Alcala, Alcala de Henares, Spain. Department of Endocrinology, Hospital Infantil Universitario Nino Jesus, Instituto de Investigacion La Princesa, Madrid, Spain. Centro de Investigacion Biomedica en Red de Fisiopatologia Obesidad y Nutricion (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain.",
     "LA": [
          "eng"
     ],
     "PT": [
          "Journal Article",
          "Research Support, Non-U.S. Gov't"
     ],
     "DEP": "20151106",
     "PL": "England",
     "TA": "J Neurochem",
     "JT": "Journal of neurochemistry",
     "JID": "2985190R",
     "RN": [
          "0 (Amyloid beta-Peptides)",
          "0 (Receptors, Somatostatin)",
          "4TI98Z838E (Estradiol)",
          "51110-01-1 (Somatostatin)",
          "67763-96-6 (Insulin-Like Growth Factor I)"
     ],
     "SB": "IM",
     "MH": [
          "Alzheimer Disease/metabolism",
          "Amyloid beta-Peptides/*metabolism",
          "Animals",
          "Cell Death/drug effects",
          "Estradiol/*pharmacology",
          "Female",
          "Hippocampus/*drug effects/metabolism",
          "Insulin-Like Growth Factor I/*metabolism",
          "Rats, Wistar",
          "Receptors, Somatostatin/*metabolism",
          "Signal Transduction/*drug effects",
          "Somatostatin/metabolism"
     ],
     "OTO": [
          "NOTNLM"
     ],
     "OT": [
          "Alzheimer's disease",
          "IGF-I signaling",
          "Neprilysin",
          "estradiol",
          "somatostatin",
          "beta-amyloid"
     ],
     "EDAT": "2015/10/08 06:00",
     "MHDA": "2016/08/23 06:00",
     "CRDT": [
          "2015/10/08 06:00"
     ],
     "PHST": [
          "2015/03/27 00:00 [received]",
          "2015/09/11 00:00 [revised]",
          "2015/09/14 00:00 [accepted]",
          "2015/10/08 06:00 [entrez]",
          "2015/10/08 06:00 [pubmed]",
          "2016/08/23 06:00 [medline]"
     ],
     "AID": [
          "10.1111/jnc.13381 [doi]"
     ],
     "PST": "ppublish",
     "SO": "J Neurochem. 2015 Dec;135(6):1257-71. doi: 10.1111/jnc.13381. Epub 2015 Nov 6.",
     "term": "hippocampus"
}